More than 30 years experience in finance and public accounting for private and public companies; has participated directly in $4 billion of corporate financing; Management in biotech industry includes BioReliance, Human Genome Sciences, and CoGenesys. Joined HGS in 1992 at its founding and served as VP of Finance; Part of the team that spun Cogenesys out from HGS in 2006 and was its’ CFO until it was sold to Teva Pharma in 2008 for $400 M

In-depth experience in the research, development of diagnostic products in clinical chemistry and rapid microbiology; Founder of Axo Diagnostics; Vice President of Product Development at Celsis-Lumac; Director of Assay Development at IGEN; Director – Chemistry R&D, Dade Stratus; Experience in both large and startup organizations, in management and lab level, in assay and systems development for unit-dose devices and high throughput instruments.

VP Diagnostics at IGEN; developed a breakthrough luminescent immunoassay technology for measuring proteins and DNA in biological fluids, Licensed to Roche, Eisai Inc., Akzo Pharma and ABI/Perkin Elmer, Positioned IGEN for an IPO and sale to Roche for $1.5 billion in 2005.
Prior to IGEN, at Abbott Laboratories; strategic marketing and management of large R&D programs that developed chemistry instrumentation and reagents for diagnostic market.

VP Diagnostics at IGEN; developed a breakthrough luminescent immunoassay technology for measuring proteins and DNA in biological fluids, Licensed to Roche, Eisai Inc., Akzo Pharma and ABI/Perkin Elmer, Positioned IGEN for an IPO and sale to Roche for $1.5 billion in 2005.
Prior to IGEN, at Abbott Laboratories; strategic marketing and management of large R&D programs that developed chemistry instrumentation and reagents for diagnostic market.